We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK’s price watchdog recommended against the reimbursement of Roche’s Cotellic and Zelboraf for the treatment of BRAF V600 mutation-positive melanoma, citing the expensive list price for the products. Read More
The New York attorney general’s office is conducting an investigation to determine if Mylan engaged in anticompetitive practices when entering contracts to sell its allergy therapy EpiPen to schools. Read More
Heart Metabolics launched an open-label Phase IIb study of perhexiline in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure with preserved left ventricular function. Read More
The UK’s price watchdog has recommended reimbursement for Bayer’s prostate cancer drug Xofigo for an expanded indication, provided that the company delivers discounted prices as promised. Read More